中國醫藥(600056.SH):卡貝縮宮素注射液獲得藥品補充申請批準通知書
格隆匯6月27日丨中國醫藥(600056.SH)公佈,下屬全資子公司海南通用三洋藥業有限公司(簡稱“三洋藥業”)收到國家藥品監督管理局覈準簽發的卡貝縮宮素注射液《藥品補充申請批準通知書》,卡貝縮宮素作爲一種新型的人工合成的具有激動劑性質的長效縮宮素類似物,其可以與子宮平滑肌的催產素受體結合,使子宮收縮同步化、規律化,收縮增強並延長收縮時間,用於選擇性硬膜外或腰麻下剖宮產手術,以預防子宮收縮乏力和產後出血,其起效快、作用時間長、臨牀應用安全,能夠有效控制產後出血及分娩過程中的出血。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.